Pressmaster /
6 April 2016Asia

Life sciences organisations agree antibody drug development deal

MRC Technology and the Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have agreed a partnership that will help develop new therapeutic antibodies.

IPS-CAS has experience in research into infectious diseases and generating antibodies while MRC is a medical research charity.

Together, the two bodies have created the IPS-MRCT Joint Centre for Therapeutic Antibodies in order to combine their expertise in research and development, intellectual property protection and efficient technology transfer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at